Unique C1 inhibitor dysfunction in a kindred without angioedema. I. A mutant C1 INH that inhibits C1-s but not C1-r.
We have described hereditary incomplete deficiency of the fourth component of complement (C4) in 10 members of a large kindred. C4 deficiency in this kindred is not linked to C4 loci in the HLA region. C4 synthesis is decreased, and C4 catabolism is normal in kindred members with low serum C4 levels. We have discovered a uniquely dysfunctional C1 inhibitor in all C4-deficient members of this kindred. C1 inhibitor dysfunction is revealed by incubating sera of affected members with EDTA, which destroys all C4 activity in these sera, but not in normal sera or sera from individuals with partial C4 deficiencies. The M(r) of C1 inhibitor purified from affected members is normal, but approximately 50% of this C1 inhibitor resists cleavage by trypsin (0.14 microM) at arg444, suggesting a substitution at this position. Moderate increases in trypsin, however, result in cleavage of the resistant molecules, which would not be expected if arg444 were the site of the mutation. All molecules in C1 inhibitor purified from affected members' plasma bind to activated C1s (C1-s), but approximately 50% of molecules in these preparations do not bind to activated C1r (C1r). These findings show that affected kindred members have a unique mutation in C1 inhibitor. The mutant C1 inhibitor does not prevent the activation of C1s by C1-r when serum Ca2+ is chelated by EDTA, but its inhibition of C1-s is normal in vivo, as shown by normal C2 levels, normal C4 catabolism, and absence of angioedema in C4-deficient members. The nature of the mutation, its selective failure to inhibit C1-r, and its relationship to decreased C4 synthesis remain to be defined.
Wisnieski
J J
JJ
Department of Veterans Affairs Medical Center, Cleveland, Ohio 44106.
Knauss
T C
TC
Yike
I
I
Dearborn
D G
DG
Narvy
R L
RL
Naff
G B
GB
D000799:Angioedema / Q000276:immunology; D003174:Complement C1 Inactivator Proteins / Q000032:analysis / Q000235:genetics / Q000502:physiology*; D015923:Complement C1r / Q000378:metabolism*; D003173:Complement C1s / Q000378:metabolism*; D003175:Complement C2 / Q000502:physiology; D003181:Complement C4 / Q000172:deficiency* / Q000502:physiology; D004492:Edetic Acid / Q000494:pharmacology; D004533:Egtazic Acid / Q000494:pharmacology; D006801:Humans; D009154:Mutation; D014357:Trypsin / Q000494:pharmacology
D003174:Complement C1 Inactivator Proteins; D003175:Complement C2; D003181:Complement C4; D004533:Egtazic Acid; D004492:Edetic Acid; D014357:Trypsin; D015923:Complement C1r; D003173:Complement C1s